Chen D - Search Results

1

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Chen D, Xu J, Qiao R, Zhao Y, Chu T, Han B, Zhong R. Chen D, et al. J Oncol. 2020 Nov 19;2020:8811487. doi: 10.1155/2020/8811487. eCollection 2020. J Oncol. 2020. PMID: 33643409 Free PMC article.

2

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases.

Qiao R, Zhong R, Xu J, Zhang Y, Zhang B, Wang S, Lou Y, Chen D, Chang Q, Zhao Y, Han B. Qiao R, et al. Among authors: chen d. J Cardiothorac Surg. 2019 Mar 29;14(1):63. doi: 10.1186/s13019-019-0886-y. J Cardiothorac Surg. 2019. PMID: 30925891 Free PMC article.

3

The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer.

Chen D, Chu T, Chang Q, Zhang Y, Xiong L, Qiao R, Teng J, Han B, Zhong R. Chen D, et al. Ann Transl Med. 2019 May;7(9):195. doi: 10.21037/atm.2019.04.06. Ann Transl Med. 2019. PMID: 31205913 Free PMC article.

4

Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.

Chen D, Xu J, Zhao Y, Chu T, Zhong H, Han B, Zhong R. Chen D, et al. J Cancer Res Clin Oncol. 2020 Feb;146(2):401-406. doi: 10.1007/s00432-019-03064-1. Epub 2019 Nov 6. J Cancer Res Clin Oncol. 2020. PMID: 31691871

5

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient.

Zhong R, Zhang Y, Chen D, Cao S, Han B, Zhong H. Zhong R, et al. Among authors: chen d. Cancer Immunol Immunother. 2021 Aug;70(8):2261-2274. doi: 10.1007/s00262-021-02848-0. Epub 2021 Jan 27. Cancer Immunol Immunother. 2021. PMID: 33506299 Free PMC article.

6

Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer.

Chen D, Xu J, Zhao Y, Han B, Zhong R. Chen D, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2331273. doi: 10.1080/15384047.2024.2331273. Epub 2024 Mar 27. Cancer Biol Ther. 2024. PMID: 38536706 Free PMC article.

7

NCAPD2 serves as a potential prognostic biomarker for lung adenocarcinoma and promotes cell proliferation, migration, invasion and cell cycle in vitro.

Wu P, Zhao L, Zhang H, Lou Y, Chen D, Xue S, Liu X, Jiang H. Wu P, et al. Among authors: chen d. Oncol Res. 2024 Aug 23;32(9):1439-1452. doi: 10.32604/or.2024.047490. eCollection 2024. Oncol Res. 2024. PMID: 39220139 Free PMC article.

8

RILPL2 as a potential biomarker for predicting enhanced T cell infiltration in non-small cell lung cancer.

Chen D, Zhang H, Zhao L, Liu X, Lou Y, Wu P, Xue S, Jiang H. Chen D, et al. Immunol Res. 2024 Oct;72(5):1174-1184. doi: 10.1007/s12026-024-09520-6. Epub 2024 Jul 30. Immunol Res. 2024. PMID: 39078518 Free PMC article.

9

Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.

Wang X, Chen D, Shi Y, Luo J, Zhang Y, Yuan X, Zhang C, Shu H, Yu W, Tian J. Wang X, et al. Among authors: chen d. Front Immunol. 2023 Apr 20;14:1123231. doi: 10.3389/fimmu.2023.1123231. eCollection 2023. Front Immunol. 2023. PMID: 37153542 Free PMC article.

10

Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.

Chen D, Zhang H, Zhao L, Liu X, Xue S, Wu P, Jiang H. Chen D, et al. Cell Cycle. 2023 Apr;22(7):841-857. doi: 10.1080/15384101.2022.2159203. Epub 2022 Dec 19. Cell Cycle. 2023. PMID: 36536539 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33,664 results

Search Page

Filters